Pharmaceutical giant Eli Lilly (NYSE: LLY) has gotten off to an incredible start in 2024.

The company's diabetes and obesity care treatments, Mounjaro and Zepbound, continue to support unprecedented growth for Lilly in a heated race with its rival Novo Nordisk, the maker of glucagon-like peptide 1 (GLP-1) agonists Ozempic, Wegovy, Rybelsus, and Saxenda.

Although GLP-1 medications are in the spotlight for Lilly, investors should be keen to learn that the company just achieved another milestone.

Continue reading

Source Fool.com